Back to results
US 2023/0151037 A1Published application
Gpr40 agonists
AssigneeKallyope, Inc.
InventorsIyassu SEBHAT, Shuwen HE, Simon MATHIEU
Life of this patent
Estimating the term…
Abstract
This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
Claims54
A compound of Formula (I):
- or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, wherein:
- Z is —P(═O)(H)OR6, —P(═O)(R5)OR6, —P(═O)(OR6)2, —S(═O)(OR6), —SO2OR6, —C(═O)NHSO2R5, —C(═O)NHSO2N(R6)2, —N(R6)SO2N(R6)2, —N(R6)C(═O)NHSO2(R5), —N(R6)C(═O)NHSO2N(R6)2, —N(R6)C(═NH)NH2, —C(═O)NHNHC(═O)N(R6)2, or —B(OR6)2;
- R5 is C1-C6 alkyl, C3-C6 cycloalkyl, phenyl, or —(C1-C6 alkyl)-phenyl;
- wherein each alkyl, cycloalkyl, and phenyl is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of halogen, —CN, —OH, —O—(C1-C6 alkyl), C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 hydroxyalkyl, —O—(C1-C6 fluoroalkyl), C3-C6 cycloalkyl, and 3- to 6-membered heterocycloalkyl;
- each R6 is independently hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, phenyl, or —(C1-C6 alkyl)-phenyl;
- wherein each alkyl, cycloalkyl, and phenyl is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of halogen, —CN, —OH, —O—(C1-C6 alkyl), C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 hydroxyalkyl, —O—(C1-C6 fluoroalkyl), C3-C6 cycloalkyl, and 3- to 6-membered heterocycloalkyl;
- R1, R2, and R3 are each independently hydrogen, halogen, —OH, —O—(C1-C6 alkyl), C1-C6 alkyl, C3-C6 cycloalkyl, or 3- to 6-membered heterocycloalkyl;
- wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of halogen, —CN, —OH, —O—(C1-C6 alkyl), and C1-C6 alkyl;
- R4 is C1-C6 alkyl, C3-C6 cycloalkyl, or 3- to 6-membered heterocycloalkyl;
- wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of halogen, —CN, —OH, —O—(C1-C6 alkyl), and C1-C6 alkyl;
- Y1, Y2, Y3, and Y4 are each independently N, CH, or C—RY;
- each RY is independently halogen, —CN, —OH, —O—(C1-C6 alkyl), —NH2, —NH—(C1-C6 alkyl), —N(C1-C6 alkyl)2, C1-C6 alkyl, C3-C6 cycloalkyl, or 3- to 6-membered heterocycloalkyl;
- wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of halogen, —CN, —OH, —O—(C1-C6 alkyl), and C1-C6 alkyl;
- L1 is —O—, —NR7—, *—O—CH2—, *—CH2—O—, *-NR7—CH2—, *—CH2—NR7—, *-NR7—C(O)—, *-C(O)—NR7—, or *-C(O)—CH2—;
- wherein * represents the connection to Ring B;
- R7 is hydrogen, C1-C6 alkyl, or C3-C6 cycloalkyl;
- Ring B is arylene or heteroarylene;
- wherein the arylene or heteroarylene is unsubstituted or substituted with 1, 2, 3, or 4 RB substituents;
- Ring A is carbocycle or heterocycle;
- wherein the carbocycle or heterocycle is unsubstituted or substituted with 1, 2, 3, 4, or 5 RA substituents;
- L2 is a bond, C1-C6 alkylene, or —(C1-C6 alkylene)-O—;
- wherein the alkylene is unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of halogen, —CN, —OH, C1-C6 alkyl, and —O—(C1-C6 alkyl);
- each RA is independently halogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 fluoroalkyl, -LA-CN, -LA-OH, -LA-OR10, -LA-NR11R11, -LA-C(═O)R10, -LA-C(═O)OR11, -LA-OC(═O)R11, -LA-C(═O)NR11R11, -LA-NR11C(═O)R11, -LA-NR11C(═O)NR11R11, -LA-OC(═O)NR11R11, -LA-NR11C(═O)OR10, -LA-OC(═O)OR10, -LA-aryl, -LA-heteroaryl, -LA-(C3-C10 cycloalkyl), or -LA-(3- to 10-membered heterocycloalkyl);
- wherein each alkyl, alkenyl, alkynyl, fluoroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, —CN, —OH, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 hydroxyalkyl, —O—(C1-C6 alkyl), and —O—(C1-C6 fluoroalkyl);
- each RB is independently halogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 fluoroalkyl, -LB-CN, -LB-OH, -LB-OR10, -LB-NR11R11, -LB-C(═O)R10, -LB-C(═O)OR11, -LB-OC(═O)R11, -LB-C(═O)NR11R11, -LB-NR11C(═O)R11, -LB-NR11C(═O)NR11R11, -LB-OC(═O)NR11R11, -LB-NR11C(═O)OR10, -LB-OC(═O)OR10, -LB-aryl, -LB-heteroaryl, -LB-(C3-C10 cycloalkyl), or -LB-(3- to 10-membered heterocycloalkyl);
- wherein each alkyl, alkenyl, alkynyl, fluoroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, —CN, —OH, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 hydroxyalkyl, —O—(C1-C6 alkyl), and —O—(C1-C6 fluoroalkyl);
- each LA and LB is independently a bond or C1-C6 alkylene;
- wherein the alkylene is unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of halogen, —CN, —OH, —O—(C1-C6 alkyl), and C1-C6 alkyl;
- each R10 is independently C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 3- to 10-membered heterocycloalkyl, phenyl, or monocyclic heteroaryl;
- wherein each alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, —CN, —OH, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 hydroxyalkyl, —O—(C1-C6 alkyl), and —O—(C1-C6 fluoroalkyl);
- and
- each R11 is independently hydrogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 3- to 10-membered heterocycloalkyl, phenyl, or monocyclic heteroaryl;
- wherein each alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, —CN, —OH, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 hydroxyalkyl, —O—(C1-C6 alkyl), and —O—(C1-C6 fluoroalkyl);
- or two R11 on the same nitrogen atom are taken together with the nitrogen to which they are attached to form a 3- to 10-membered N-heterocycloalkyl;
- wherein the heterocycloalkyl is unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, —CN, —OH, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 hydroxyalkyl, —O—(C1-C6 alkyl), and —O—(C1-C6 fluoroalkyl).
32 more elements
Dependencies are inferred from the claim text.